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Enzyme replacement therapy has the potential to delay or reverse adverse cardiac
remodeling in Anderson-Fabry disease (AFD); however, the current indications for enzyme
replacement therapy rely on detecting relatively advanced features of the disease. We aimed
to determine the relation between the serum N-terminal pro-brain natriuretic peptide
(NT-proBNP) concentration and cardiac abnormalities in patients with AFD. We
hypothesized that it might help to detect early disease. NT-proBNP was measured under at
rest conditions in 117 patients with AFD (age 48 – 15 years, 46.2% men). All patients
underwent clinical evaluation with electrocardiography and echocardiography. The median
NT-proBNP concentration was 24 pmol/L (range <5 to 6,059). Of the 117 patients, 67 (57%)
had elevated, age-corrected, NT-proBNP levels. In the 56 patients (48%) with normal
echocardiographic ﬁndings, the NT-proBNP levels were greater than the age-predicted
cutoffs in 10 of 25 patients with abnormal electrocardiographic ﬁndings and 3 of 31 patients
with normal electrocardiographic ﬁndings (p <0.05). On multiple regression analysis, age,
creatinine, left atrial volume index, E/Ea, and the presence of abnormal electrocardio-
graphic ﬁndings were independently associated with log NT-proBNP (R2[ 0.67, p <0.05).
In conclusion, NT-proBNP concentrations were elevated in patients with AFD and early
cardiac involvement, suggesting its measurement could assist in decisions regarding the
timing of enzyme replacement therapy. ! 2013 Elsevier Inc. All rights reserved. (Am J
Cardiol 2013;111:111e117)
Anderson-Fabry disease (AFD) is an X-linked lysosomal
storage disorder, caused by deﬁciency of a-galactosidase A.
This leads to accumulation of glycosphingolipid in tissues
throughout the body and subsequent organ failure. In the
heart, this typically manifests as left ventricular hyper-
trophy, which can progress to systolic and diastolic heart
failure.1 Enzyme replacement therapy (ERT) has the
potential to delay or reverse adverse cardiac remodeling.2,3
However, the current indications for ERT rely on the
detection of relatively advanced features of the disease,
when irreversible organ damage may have occurred.4,5
Brain natriuretic peptide is a cardiac neurohormone secreted
from the ventricles of the heart in response to increased wall
stress. Brain natriuretic peptide and the N-terminal fragment
of its pro-hormone (NT-proBNP) have an established role in
determining the diagnosis and prognosis of heart failure.6e8
In a male mouse knockout model for Fabry’s disease, the
brain natriuretic peptide mRNA levels were signiﬁcantly
increased compared to that of wild-type controls, despite
a mild cardiac phenotype.9 NT-proBNP has recently been
associated with overall disease severity in AFD10; however,
its role as a marker of early cardiac involvement has not
been examined. The primary aim of the present study was to
determine the relation between NT-proBNP levels and
conventional markers of cardiac involvement in AFD.
Methods
This was an observational, cross-sectional cohort study.
Data were collected prospectively. The cohort consisted of
consecutively evaluated patients with AFD, seen at a dedi-
cated cardiomyopathy clinic from April 2008 to April 2011.
The diagnosis of AFD was determined by measuring the
plasma and/or leukocyte a-galactosidase A enzyme activity,
followed by sequencing of the a-galactosidase A gene. All
patients were aged !18 years at evaluation. The study
conformed to the principles of the Helsinki declaration.
All patients were evaluated clinically using a 12-lead
electrocardiogram at rest and echocardiography. The New
York Heart Association class, current medication, and blood
pressure were recorded. The Mainz severity score index was
used as an index of overall disease severity.11 Serum
creatinine was used to estimate the glomerular ﬁltration rate
using the 4-variable Modiﬁcation of Diet in Renal Disease
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equation.12 NT-proBNP was measured from routine venous
blood samples taken at rest.
The venous blood samples were drawn into serum
separator tubes and sent to the laboratory for quantiﬁcation
the same day as routine sample analysis. Serum NT-proBNP
was measured using a 2-site electrochemiluminescence
immunoassay on a Roche E170 analyzer. The results are
reported in pmol/L, with a lower limit of detection of 5
pmol/L. The manufacturer’s guidelines, derived from 1,981
blood donors aged 18 to 65 years and 283 subjects with no
known cardiac disease aged 50 to 90 years, were used to
deﬁne normal values (Supplemental ﬁle S1). Values greater
than the 97.5th percentile for age and gender were consid-
ered abnormal.
Standard 12-lead electrocardiograms were recorded at
25 mm/s and 10 mm/mV. The rhythm, heart rate, PR
interval duration, and QRS complex duration were
measured in milliseconds. A QRS duration >120 ms, PR
interval <120 ms, or PR interval >200 ms was considered
abnormal. Left ventricular (LV) hypertrophy was assessed
using the Sokolow-Lyon and Cornell criteria.13,14 Patients
were considered to have electrocardiographic (ECG)
evidence of LV hypertrophy if they met 1 or both criteria.
Repolarization changes were assessed in 3 regions: inferior
(leads II, II, and aVF), anterior (leads V1 to V4), and lateral
(leads V5 to V6, I, and aVL). Patients with T-wave inver-
sion in !1 of these regions were classiﬁed as having
repolarization abnormalities. Abnormal ECG ﬁndings were
deﬁned as !1 of the following: conduction disease
(abnormal QRS duration or PR interval); repolarization
changes; and LV hypertrophy according to the voltage
criteria.
Patients with a paced rhythm were grouped according to
ECG abnormalities present before pacemaker implantation.
Transthoracic echocardiography was performed with the
patient in the left lateral decubitus position with commer-
cially available equipment (M3S Probe, Vivid i or Vivid 7;
GE-Vingmed, Horten, Norway). The images were stored
digitally for off-line analysis (EchoPac, version 108.1.5;
GE-Vingmed). Complete 2-dimensional, color, pulsed, and
continuous wave Doppler images were acquired using
standard techniques. The LV ejection fraction was calcu-
lated using Simpson’s biplane method.15 The left atrial
volumes were calculated using the ellipsoid model and
indexed the to body surface area (left atrial volume
index).16 The relative wall thickness was calculated as
(interventricular septal thickness at diastole þ posterior wall
thickness in diastole)/LV end-diastolic diameter and is
expressed as a percentage. The LV mass was calculated
using the Devereux cubed formula (0.8 # {1.04 # [(LV
end-diastolic diameter þ posterior wall thickness in
diastole þ interventricular septal thickness at dia-
stole)3$(LV end-diastolic diameter)3]} þ 0.6 g) and
indexed to the body surface area to obtain the LV mass
index.17 Patients with a normal LV mass index were clas-
siﬁed as having concentric remodeling in the presence of
a relative wall thickness >42% or normal geometry if the
relative wall thickness was %42%. Patients with an
increased LV mass index were classiﬁed as having
concentric hypertrophy if the relative wall thickness
was >42% or eccentric hypertrophy if the relative wall
Table 1
Clinical and echocardiographic characteristics of study population
(n ¼ 117)
Clinical Characteristics Value
Male gender 54 (46%)
Age (yrs)
Mean ' SD 48 ' 15
Range 19e79
Mainz severity score index
Mean ' SD 20 ' 11
Range 1e53
Creatinine (mmol/L)
Mean ' SD 91 ' 76
Range 43e692
Glomerular ﬁltration rate (ml/min/1.73 m2)
Mean ' SD 87 ' 27
Range 7e158
Hemoglobin (g/dl)
Mean ' SD 13.2 ' 1.4
Range 8.9e16.7
Systolic blood pressure (mm Hg)
Mean ' SD 118 ' 16
Range 84e165
Diastolic blood pressure (mm Hg)
Mean ' SD 72 ' 10
Range 40e91
Heart rate (beats/min)
Mean ' SD 64 ' 12
Range 38e93
Medications
Enzyme replacement therapy 97 (83%)
b Blocker 23 (20%)
Angiotensin-converting enzyme inhibitor 37 (32%)
Angiotensin II receptor blocker 15 (13%)
New York Heart Association class
I 75 (64%)
II 33 (28%)
III 9 (8%)
Rhythm
Sinus rhythm 102 (87%)
Atrial ﬁbrillation 4 (3%)
Paced rhythm 11 (9%)
Atrial ﬁbrillation
Paroxysmal 13 (11%)
Persistent 4 (3%)
Echocardiographic ﬁndings
Ejection fraction (%)
Mean ' SD 61 ' 6
Range 31e74
Left ventricular end-diastolic diameter (mm)
Mean ' SD 48 ' 5
Range 36e61
Left ventricular mass index (g/m2)
Mean ' SD 113 ' 45
Range 49e332
Left atrial size (mm)
Mean ' SD 39 ' 7
Range 27e58
Left atrial volume index (ml/m2)
Mean ' SD 25 ' 10
Range 12e60
Left ventricular outﬂow tract obstruction 3 (3%)
Remodeling
Normal 47 (40%)
Concentric 16 (13%)
Concentric hypertrophy 45 (39%)
Eccentric hypertrophy 9 (8%)
Data are presented as n (%) or mean ' SD and range.
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thickness was %42%.14 Diastolic dysfunction was graded
according to the mitral inﬂow pattern, pulmonary vein ﬂow,
and tissue Doppler indexes at the lateral mitral annulus and
classiﬁed as normal, mild (impaired relaxation), moderate
(pseudonormal), or severe (restrictive).18 An estimate of LV
ﬁlling pressure was made using the ratio between trans-
mitral peak E velocity and the peak Ea velocity measured at
the lateral wall (E/Ea).19 The Tei LV performance index
was calculated using pulsed wave spectral Doppler traces of
the LV outﬂow tract and transmitral inﬂow.20 The LV
outﬂow tract gradients were measured at rest and after
provocation with the Valsalva maneuver. LV outﬂow tract
obstruction was deﬁned as a gradient of !30 mm Hg. In the
present study, abnormal echocardiographic ﬁndings were
deﬁned as either interventricular septal thickness at diastole
or posterior wall thickness in diastole of !13 mm or LV
mass index of !95 g/m2 in women and !115 g/m2 in
men.16
The data were analyzed using PAWS statistical software,
version 18.0. Continuous variables are presented as the
mean ' SD and categorical variables as frequencies and
percentages. Logarithmic transformation allowed the
NT-proBNP concentration to be treated as a normally
distributed variable. Bivariate correlation analysis was per-
formed using linear regression. To identify independent
correlates of logNT-proBNP, all variables with p <0.05 on
univariate analysis were included in a forward elimination
multivariate regression analysis. Receiver operating char-
acteristics curve analysis was performed to test the ability of
NT-proBNP to detect cardiac involvement, deﬁned by either
abnormal ECG or echocardiographic ﬁndings. Fisher’s
exact test was used to calculate the signiﬁcance of the
observed data. The 95% conﬁdence intervals were 2-sided
with an a level of 5%.
Results
During a 3-year period, 117 patients were studied:
54 (46.2%) were men, with a mean age of 48 ' 15 years.
The clinical and echocardiographic characteristics of the
study population are listed in Table 1. The median
NT-proBNP concentration was 24 pmol/L (range <5 to
6,059). Of the 117 patients, 67 (57%) had elevated, age-
corrected, NT-proBNP levels. Three patients had an
NT-proBNP concentration >1,000 pmol/L, two with end-
stage renal failure, who required hemodialysis (6,063 and
4,139 pmol/L), and one with advanced mesothelioma
(1,487 pmol/L). These patients were considered outliers and
were excluded from the subsequent correlation analysis.
The NT-proBNP concentrations were greater in the
men and correlated with age (Figure 1). The values in
patients not receiving ERT (n ¼ 20) ranged from <5 to
1,487 pmol/L. The NT-proBNP concentration also increased
according to the New York Heart Association class
(Figure 2) and grade of diastolic dysfunction (Figure 3). The
LogNT-proBNP correlated with the Mainz severity score
index score, systolic blood pressure, serum creatinine,
and echocardiographic indexes of LV function (E/Ea
Figure 1. NT-proBNP increases with age in men and women (n ¼ 114).
Figure 3. NT-proBNP is a marker of diastolic dysfunction (n ¼ 109).
Diastolic function was unable to be accurately classiﬁed in 5 patients
because of heart rhythm or missing values.
Figure 2. NT-proBNP increases with New York Heart Association func-
tional class (n ¼ 114).
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and Tei index; Table 2). No relation was seen between
LogNT-proBNP and LV size, ejection fraction, or LV
outﬂow tract obstruction. In a multivariate linear regression
model, LogNT-proBNP independently correlated with age,
serum creatinine, left atrial volume index, the E/Ea ratio,
and abnormal ECG ﬁndings (R2 ¼ 0.67, p <0.05).
Of the 117 patients, 61 (53%) had abnormal ECG and
echocardiographic ﬁndings, 25 had abnormal ECG ﬁndings
but a normal wall thickness and LV mass index on the
echocardiogram, and 31 had normal ECG and echocardio-
graphic ﬁndings (Figure 4). In the 56 patients (47.9%) with
normal echocardiographic ﬁndings, the NT-proBNP levels
Table 2
Relation between log N-terminal pro-brain natriuretic peptide (NT-proBNP) and echocardiographic and clinical parameters (n ¼ 114)
Parameter Univariate Multivariate
b Coefﬁcient p Value b Coefﬁcient p Value
Age (yrs) 0.656 <0.0001 0.265 0.001
Male gender 0.129 0.171
Mainz severity score index 0.514 <0.0001 — NS
Systolic blood pressure (mm Hg) 0.170 0.07
Glomerular ﬁltration rate (ml/min/1.73 m2) $0.585 <0.0001 $0.188 0.012
Abnormal electrocardiographic ﬁndings 0.518 <0.0001 0.155 0.024
Ejection fraction (%) 0.013 0.887
Left ventricular end-diastolic diameter (mm) $0.118 0.213
Left atrial volume index (mls/m2) 0.610 <0.0001 0.272 <0.001
Left ventricular mass index (g/m2) 0.616 <0.0001 — NS
Right ventricular hypertrophy 0.437 <0.0001 — NS
E/Ea 0.642 <0.0001 0.236 0.002
E/A ratio $0.288 <0.0001 — NS
Tei index 0.292 0.002 — NS
Mitral regurgitation 0.365 <0.0001 — NS
Left ventricular outﬂow tract obstruction 0.179 0.056
Figure 4. (A) Population stratiﬁed according to ECG and echocardiographic ﬁndings (n ¼ 117). (B) NT-proBNP stratiﬁed according to ECG and echocar-
diographic abnormalities (n ¼ 114). (C) Subgroup analysis indicated NT-proBNP levels were greater in those with both LV hypertrophy and repolarization
changes (n ¼ 114).
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were greater than the age-predicted cutoffs in 10 of the
25 patients with abnormal ECG ﬁndings (range 12 to
129 pmol/L) and in 3 of the 31 patients with normal ECG
ﬁndings (range 15 to 55 pmol/L; p <0.05). All these
patients were normotensive with systolic blood pressure
of %130 mm Hg. No patient had normal ECG ﬁndings with
abnormal echocardiographic ﬁndings.
Patients with abnormal ECG and echocardiographic
ﬁndings had signiﬁcantly greater NT-proBNP concentra-
tions (median 72 pmol/L, range <5 to 6,063) than those
with normal ﬁndings (median 12 pmol/L, range <5 to 129)
or abnormal ECG ﬁndings alone (median 72 pmol/L, range
<5 to 55; Figure 4). A subgroup analysis of ECG abnor-
malities showed a nonsigniﬁcant trend toward greater
NT-proBNP levels in patients with repolarization changes
than in those with ECG evidence of LV hypertrophy alone
(Figure 4). The area under the receiver operating charac-
teristics curve was 0.85 (95% conﬁdence interval 0.79 to
0.92). An NT-proBNP level of !20 pmol/L had a positive
predictive value of 99.7% and negative predictive value of
9.2% to identify abnormal ECG or echocardiographic
ﬁndings (Table 3).
Discussion
The results of the present study have demonstrated that
plasma NT-proBNP is elevated in patients with cardiac
manifestations of AFD and correlates with symptom class
and echocardiographic surrogates of elevated LV ﬁlling
pressure. Increased NT-proBNP concentrations were found
in patients without echocardiographic evidence of LV
hypertrophy, suggesting that measurement of natriuretic
peptides could be a useful adjunctive test in identifying
patients with early subclinical cardiac disease.
The cardinal histologic feature of AFD-related cardiac
disease is the accumulation of globotriaosylceramide in
cardiomyocytes, conduction system cells, valvular ﬁbro-
blasts, endothelial cells, and vascular smooth muscle
cells.1,21 Electron microscopy of cardiomyocytes typically
shows a paucity of myoﬁbrillar material and membrane-
lined vacuoles ﬁlled with lamellar electron-dense inclu-
sions.22 In addition to the distortion of normal cellular
architecture, it has been postulated that globotriaosylcer-
amide accumulation triggers intracellular signaling
pathways that lead to cardiomyocyte hypertrophy,
apoptosis, and necrosis and interstitial ﬁbrosis.23 Micro-
vascular ischemia and mitochondrial dysfunction might also
play a role in disease progression.24,25
ERT is recommended for patients with obvious mani-
festations of AFD to mitigate the risk of future cardiac,
cerebrovascular, and neurologic complications.26 In most
studies, clinically signiﬁcant cardiac disease has been
deﬁned by the presence of myocardial hypertrophy on
echocardiograms; however, numerous reports have sug-
gested that this is a relatively late phenomenon (particularly
in women) often associated with the presence of irreversible
myocardial scarring on cardiac magnetic resonance
imaging.27 A number of studies have examined the ability of
more sensitive echocardiographic methods such as tissue
Doppler imaging to detect early disease; however, as with
all Doppler techniques, these have been only modestly
reproducible and lack speciﬁcity.28
Compared against conventional electrocardiography
and 2-dimensional echocardiography, NT-proBNP was
highly predictive for the presence of cardiac involvement.
Although a positive correlation was seen with the LV
mass, this was not signiﬁcant on multivariate analysis. In
contrast, markers of diastolic impairment (left atrial size
and E/Ea, reﬂecting the LV ﬁlling pressure) were inde-
pendent predictors of NT-proBNP.29 Diastolic dysfunction
in AFD has been attributed to myocardial ﬁbrosis and Gb3
accumulation and is recognized to precede hypertrophy.28
Even in subclinical disease, evidence has been found of
impaired contractility of cardiomyocytes and greater
tension of the myoﬁlament at rest.30 Therefore,
a biomarker that correlates with tension-related remodeling
would be potentially useful to identify early cardiac
involvement in AFD.
At present, ERT for AFD is only licensed for use in
patients with clear evidence of tissue damage. LV hyper-
trophy is the most widely used clinical marker of cardiac
involvement in patients with AFD; however, the results
of the present study have suggested that elevated
NT-proBNP is a useful surrogate for early cardiac disease
and could be used to justify earlier use of ERT. As
a biomarker, it is readily available to all physicians and
can be measured more frequently and economically than
performing electrcardiography and echocardiography. We
Table 3
Operating characteristics of N-terminal pro-brain natriuretic peptide (NT-proBNP) thresholds in Anderson-Fabry disease (AFD) (n ¼ 117)
NT-proBNP (pmol/L) Sensitivity
(%)
Speciﬁcity
(%)
Positive
Predictive Value (%)
Negative
Predictive Value (%)
Accuracy
(%)
Ability to predict cardiac involvement*
!5 90.7 29.0 81.9 46.8 77.1
!20 68.6 93.5 99.7 9.2 69.4
!50 53.5 96.8 99.9 4.4 54.4
!100 31.4 100.0 100.0 0.0 31.4
Ability to predict abnormal echocardiographic ﬁndings
!5 96.7 26.8 65.5 84.9 68.0
!20 83.6 82.1 96.0 49.5 83.4
!50 67.2 89.3 97.7 29.0 70.1
!100 42.6 98.2 99.8 6.4 44.7
* Echocardiographic or electrocardiographic ﬁndings.
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suggest !20 pmol/L is likely to be associated with cardiac
involvement in AFD and should prompt additional
investigation. Additional work is needed to determine
whether NT-proBNP can be used to monitor disease
progression and determine the prognosis.
The NT-proBNP concentrations found in the present
study were lower than those reported by Torralba-Cabeza
et al,10 in which the mean NT-proBNP level was 1,012 '
3,469 pg/ml (range 5 to 27,161), equivalent to 120 pmol/L.
However, their study included 7 patients who required
hemodialysis, potentially biasing their data.10 In our study,
exceptionally high levels were also seen in those with
advanced renal failure; however, we did not identify any
patients in whom severe renal dysfunction was present
without evidence of some degree of cardiac involvement.
The study population represented a cross-section of adult
patients with AFD, and although it was performed at
a cardiac center, many patients were seen for routine cardiac
screening rather than management of established cardiac
disease.
The NT-proBNP concentrations are increased in patients
with AFD and correlate with noninvasive markers of dia-
stolic dysfunction. Increased NT-proBNP levels were
present in patients without echocardiographic evidence of
LV hypertrophy. These ﬁndings suggest that measurement
of the NT-proBNP levels might assist in decisions on the
timing of ERT. Its role as a surrogate marker for the
response to therapy requires additional study.
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